Status:
NOT_YET_RECRUITING
Pharmacokinetic Study in the Biliary Complications During Liver Transplantation
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Liver Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
Liver transplantation is the last treatment for severe liver diseases such as advanced cirrhosis or fulminant hepatitis. This is a heavy treatment can be associated with numerous complications, partic...
Detailed Description
This is a prospective observational descriptive monocentric study. As the biliary and blood samples taken are not part of standard patient management, this is a type 3 study involving human subjects. ...
Eligibility Criteria
Inclusion
- Adult
- Social security coverage
- Liver transplant recipient
- Hospitalized at CHUGA
- Presenting biliary complications following liver transplantation, confirmed morphologically by ultrasound, CT scan, or liver MRI:
- Biliomas / bilioperitoneum
- Hepatic abscess as described by the radiologist
- Undergoing biliary endoscopy or radiological drainage following the initiation of antibiotic therapy (between H0-H96 and 6 weeks +/- 2 weeks)
- Having expressed their non-opposition to participate in this study.
Exclusion
- Patients under guardianship or deprived of liberty. Persons referred to in Articles L1121-5 to L1121-8 of the Public Health Code.
- Patients not affiliated with social security.
- Contraindication to the use of DALBAVANCIN.
- Secondary exclusion criteria:
- \- Discontinuation of antibiotic therapy before the completion of biliary dosage measurements.
Key Trial Info
Start Date :
September 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06601244
Start Date
September 15 2024
End Date
September 30 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Of Grenoble
Grenoble, France, 38700